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Abstract
Natural killer (NK) cells belong to the innate lymphoid cells. Their cytotoxic activity is regulat-
ed by the delicate balance between activating and inhibitory signals. NKp46 is a member of
the primary activating receptors of NK cells. We previously reported that the NKp46 receptor
is involved in the development of type 1 diabetes (T1D). Subsequently, we hypothesized
that blocking this receptor could prevent or hinder disease development. To address this
goal, we developed monoclonal antibodies for murine NKp46. One mAb, named NCR1.15,
recognizes the mouse homologue protein of NKp46, named Ncr1, and was able to down-
regulate the surface expression of NKp46 on primary murine NK cells following antibody in-
jection in vivo. Additionally, NCR1.15 treatments were able to down-regulate cytotoxic activ-
ity mediated by NKp46, but not by other NK receptors. To test our primary assumption, we
examined T1D development in two models, non-obese diabetic mice and low-dose strepto-
zotocin. Our results show a significantly lower incidence of diabetic mice in the NCR1.15-
treated group compared to control groups. This study directly demonstrates the involvement
of NKp46 in T1D development and suggests a novel treatment strategy for early insulitis.
Introduction
Natural killer (NK) cells of the innate immune system provide primary immune defense
against cancer and pathogens [1–4]. Their activity is controlled by a multitude of inhibitory
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and activating NK cell receptors [1]. Instigation of inhibitory receptors by major histocompati-
bility complex (MHC) class I molecules on healthy cells suppresses NK cell effector functions
[5,6]. The inhibitory receptors recognize mainly MHC class I proteins but also additional mole-
cules [5]. Activating receptors recognize various ligands that are tumor-derived, stress-induced,
pathogen-derived, or self-ligands [7,8]. Several activating receptors are expressed by NK cells,
among them NKG2D and natural cytotoxicity receptors (NCRs). The human NCR family in-
cludes three members named NKp30, NKp44 and NKp46 [1]. Mice express orthologous recep-
tor only for the human NKp46 (Ncr1) [9].
We recently reported that the murine activating receptor NKp46 (NCR1) is essential for the
development of type 1 diabetes (T1D) [10], an autoimmune disease prevalent throughout the
Western world. Currently the common treatment of this disease is based on a daily insulin in-
jection. It is well known that T1D development is T-cell dependent, yet several studies have
shown cytolytic activity of NK cells against pancreatic islet beta cells (β-cells) and their involve-
ment in the development of the disease [11–15]. In particular, we have shown the involvement
of NKp46 in NK contribution to T1D. We demonstrated that both human and mouse β-cells
express ligands for NKp46 in either healthy or T1D patients [10,16]. We showed that develop-
ment of experimental T1D was impaired in Ncr1gfp/gfp mice that lack the expression of
mNKp46. Additionally, we showed that employing active immunization to block NKp46,
through immunizing with recombinant NKp46, inhibited the development of T1D in murine
models [10]. These findings motivated us to explore new therapeutic approaches for T1D
based on manipulation of NKp46 function.
In order to accomplish this, one tactic would be to block the NKp46 ligands. However, the
precise nature of NKp46 ligands is not fully revealed. Several reports have shown that NKp46
recognizes cellular ligands expressed on tumor cells, dendritic cells, viral-infected cells, and
Langerhans β-cells [17,18]. Currently identified NKp46 ligands include viral hemagglutinins
[19], the cellular ligand vimentin [20] and the cellular co-ligands heparan sulfate proteoglycans
(HSPG) [21–23]. However, these two cellular ligands hardly present a suitable target for ma-
nipulation of NKp46 function through blocking of target cellular ligand.
Therefore, in the current study we investigated the methodology of antibody-mediated ma-
nipulation of the NKp46 function. We developed and characterized a new anti-murine NKp46
mAb named NCR1.15. Treatment of mice with NCR1.15 did not deplete NK cells, but sup-
pressed their NKp46-mediated function. In accordance, NCR1.15 treatment of T1D-prone
mice significantly prolonged the time to T1D development.
Research Design and Methods
Cells
Cells that were used in this study: YAC-1, murine lymphoma (TIB-160, ATCC); PD1.6, murine
thymic virus-induced lymphoma [24]; Ba/F3-Rae1εmouse pro-B lymphocyte ectopically ex-
pressing Rae-1εNKG2D ligand [25]; BW-hNKp46 and BW-mNKp46 T-cell lymphoma ectop-
ically expressing the murine or the human NKp46 [19].
Production of NCR1.15 mAb
Ncr1gfp/gfp 129/sv/J mice, lacking the expression of endogenous mNKp46, were used for the
production of mouse monoclonal antibodies against mNKp46. These mice were immunized
twice with 100ug/mice of mNKp46-Ig fusion protein, followed by a boost immunization and a
subsequent fusion with the mouse Sp2/0 cell line. First hybridoma screening for specific anti-
bodies was performed using ELISA. Positive hybridomas were selected and cloned several
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times to ensure monoclonality. Antibodies obtained from these clones were further character-
ized using different techniques.
Antibodies and Fusion proteins
The following antibodies were used in this study: BioLegend—anti-NKp46 mAb (clone
29A1.4), anti-CD3ε (clone145–2C11), anti-NK1.1 (clone PK136), anti-CD49b (clone DX5),
anti-CD27 (clone LG.3A10), anti-NKG2D (clone C7), anti-CD107a/LAMP-1 (clone 1D4B);
anti-CD11b (eBioscience, clone M1/70); anti-human NKp46 (461-G1,[26]); mouse IgG1, κ
control for injections, rat IgG2a, κ isotype control for FACS (BioLegend, clone RTK2758). The
Production of mNKp46-Ig, LIR1-Ig and mNKG2D-Ig as previously described [25,27,28].
ELISA
To determine the specific binding between NCR1.15 and the mNKp46 receptor plates were
coated overnight at 4°C with 5μg/ml of the recombinant proteins. Blocking buffer (PBS supple-
mented with 10%FBS) was applied for 2 hours at room temperature, after which plates were
washed with PBS with 0.05% Tween 20 (PBST) and incubated with 2 μg/ml of NCR1.15, 461-
G1or PBS for 2 hours at room temperature. Following washing with PBST biotin-conjugated
sheep anti-mouse IgG (GE Healthcare, NA931V) was added for 1 hr at 1:750 dilution. Follow-
ing washing streptavidin-HRP (Jackson, 016-030-084) diluted 1:1000 was added for 30 min.
Following washing TMB (DAKO, S1599) was added optical density was read at 650 nm
(Thermo Electron Corporation Multiskan Spectum).
Bimolecular interaction analysis
A BIAcore 3000 device fitted with CM5 sensor chips (BIAcore, Uppsala, Sweden) was used for
studying the interactions between NKp46 and NCR1.15 in conjunction with BIAevaluation
software (v4.1). To activate the chip, we used the EDC/NHS amine coupling procedure accord-
ing to the manufacturer’s protocol (BIAcore), followed by addition of NKp46, which was im-
mobilized in the different flow cells, followed by blocking the free active groups with 1 M
ethanolamine. Different analyte concentrations were injected, each followed by regeneration of
the surface using 10 mMNaOH. Data were analyzed using a 1:1 Langmuir binding model.
CD107a degranulation assay
Spleen lymphocytes were isolated 3 days following treatment and NK cells were purified using
Mouse NK Cell Enrichment Kit (Stemcell Technologies, #19755). 5X10^5 purified NK cells
were co-incubated with target cells for 2–4 hours in the presence of 0.1μg APC-coupled anti-
CD107a antibody; next cells were stained for CD3ε, NK1.1 and CD107a and analyzed using
FACSCantoII (BD Biosciences).
Quantitative Real Time PCR (qRT-PCR)
Total RNA was extracted from Fresh spleen tissue using the RNeasy Mini Kit (cat# 74104, Qia-
gen Ltd). RNA samples were stored at-80°C until further use. RNA concentration and purity
was assessed by spectrophotometry (NanoDrop ND1000 v3.7.1; NanoDrop Technologies, Del-
aware, USA). cDNA synthesis was performed using the High Capacity cDNA Reverse Tran-
scription Kit (cat# 4368814, Applied Biosystems. cDNA samples were stored at-20°C until
further use were. qRT-PCR reactions were performed using the Power SYBR Green PCR
Master Mix (cat# 4367659, Applied Biosystems) and experiments were performed using the
Applied Biosystems 7500 Real Time PCR system, software v2.0.5. Reactions cycling protocol:
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95°C for 10 min, then 40 cycles with a 2-step program (95°C for 15s, 60°C for 1 min). Expres-
sion levels of ncr1 (target gene) were normalized to β actin (reference gene). ncr1 Fw: 5- CTA
GGGCTCACAGAGGGACATAC-3, ncr1 Rev 5- CAACACCTCCTGTGATGAGTAGT-3, β
actin Fw: 5-GCATTGTTACCAACTGGGAC-3, β actin Rev: 5-GGTCTCAAACATGATCT
GGG-3.
Animals and NODmodel
6–8 weeks old C57BL/6 female mice were purchased fromHarlan Laboratories (Rehovot, Israel).
For the T1Dmodel in non-obese diabetic (NOD) strain 6–7 weeks old female mice were injected
intraperitoneally (i.p.) with 100μg antibody per mouse every other day for 16 weeks and glucose
levels were monitored. Ncr1gfp/+ heterozygous mice expressing GFP under the control ofNcr1
promoter in one allele [29] were used to assess the promoter activation levels. C57BL/6-Tg
(UBC-GFP) mice were used for several CD107a de-granulation assays. Theses transgenic mice
express enhanced Green Fluorescent Protein (EGFP) under the direction of the human ubiquitin
C promoter (UBC) in all tissues (Jackson laboratory). All mice used in this study were bred
and maintained in the local animal care facility, approved by the Institutional Animal Care
and Use Committee (IACUC) of Ben-Gurion University of the Negev (BGU). All experimental
procedures were reviewed and approved by the Institutional Animal Care and Use Committee
(IACUC) of Ben-Gurion University of the Negev (BGU’s IACUC) according to specified proto-
cols that aim to ensure animal welfare and reduce suffering (permit: IL-58–09–02).
Low-dose streptozotocin (LDSTZ)-induced diabetes
Sex- and age-matched, 9 weeks mice were injected i.p. for 5 consecutive days with streptozoto-
cin (STZ) (Sigma, S0130) dissolved in citrate buffer, pH 4.5, at a concentration of 50 mg  kg-1
body weight. Day zero was defined as the first day of STZ treatment. 50μg of NCR1.15 were in-
oculated i.p. at days-2 and 5. Glucose concentrations were measured using glucometer (Abbott
Diabetes Care, FreeStyle Lite) every other day. Statistical analysis was done by log-rank
Kaplan-Meier analysis.
Isolation of primary β-cells
Pancreata were inflated with 1 mg/ml collagenase type XI (Sigma), excised, and incubated for
27–35 min at 37°C. Digested pancreata were vortexed and filtered through a 500-μm sieve and
the pellet washed in HBSS containing 0.5% BSA (Sigma). The pellet was re-suspended in RPMI
medium 1640 (Gibco, 21875–034). Islets were collected on a 100-μm cell strainer (BD, Falcon)
and individual islets were picked by hand under the microscope and further dispersed into sin-
gle cells [30] Islets’ single cell preparations were first pooled and only then divided among the
different treatment groups.
Results
NCR1.15 mAb specifically recognizes mouse NKp46
To test whether blocking of NKp46 (Ncr1 in mice) will attenuate T1D development, we devel-
oped an anti-mouse NKp46/Ncr1 IgG1,κmAb (termed NCR1.15) that specifically recognizes
recombinant mouse NKp46 (mNKp46) but not human NKp46 (hNKp46). As a control, we
employed 461-G1 mAb that specifically recognizes hNKp46 but not mNKp46 [26] (Fig. 1A).
Both mAbs did not bind to other recombinant NK receptors such as LIR1 or to the hFc which
is fused to the recombinant NK receptors employed in the binding assays (Fig. 1A and data not
shown). NCR1.15 also recognizes BW cells that were transfected to express mNKp46 compared
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to BW cells expressing hNKp46 (Fig. 1B). NCR1.15 displayed a characteristic binding curve to
mNKp46 (KD = 1.06E-08 M), indicating binding with moderate affinity (Fig. 1C). To test
whether NCR1.15 specifically recognizes endogenous mNKp46 expressed by murine primary
NK cells, we stained splenocytes from the functionally competent Ncr1gfp/+ heterozygous mice
expressing one allele encoding for mNKp46 and the other allele encoding for GFP under the
control of Ncr1 promoter in the other allele [29]. GFP-positive splenocytes were nearly all
(99%) stained positively with NCR1.15 or with the commercial anti-mNKp46 mAb 29A1.4
and (Fig. 1D). Accordingly, the overwhelming majority of NCR1.15+ or 29A1.4+ single or dou-
ble positives were also GFP positive (Fig. 1E). To summarize, NCR1.15 specifically stained
mNKp46 expressed by murine NK cells.
Single dose treatment with NCR1.15 reduces membrane-associated
NKp46 expression and NKp46-mediated NK function
To investigate the effect of anti-mNKp46 treatment in vivo, we first inoculated C57BL/6 mice
i.p. with 100μg NCR1.15/mouse (single dose). Three days post inoculation, a fraction of NK
cells, and NKp46 expression levels were monitored for splenocytes and PBMCs (Fig. 2).
Fig. 2A shows a representative NK staining of splenocytes and Fig. 2B summarizes the NK
Fig 1. Specific binding of NCR1.15 monoclonal antibody to murine NKp46. (A) ELISA plates were coated with different NK-fusion receptors followed by
incubation with NCR1.15 or 46–1G1 mouse antibodies, the binding was detected with anti-mouse IgG HRP. Data from one representative of three
independent experiments are shown. (B) FACS analysis of NCR1.15 binding to BW cells expressing mNKp46 or hNKp46. (C) Kinetics of NCR1.15 binding to
mNKp46-Ig; the results from the Biacore analysis are expressed in resonance units (RU) against time. Dose-dependent NCR1.15 were injected over the
immobilized fusion Ig’s surface at increasing concentrations ranging from 0 to 250nM. (D-E) FACS analysis of NCR1gfp/+ splenocytes stained for NKp46 with
29A1.4 and NCR1.15 clones. Data from one representative of three independent experiments are shown. Bars, ±SD.
doi:10.1371/journal.pone.0118936.g001
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staining results (CD3-NK1.1+) for splenocytes and PBMCs from four independent experi-
ments. The NK fraction in both the spleen and blood did not change significantly following a
single dose injection of NCR1.15 compared to mock injection (isotype control or PBS). In par-
allel, we tested membrane-associated NKp46 expression following single dose injection of
NCR1.15. Fig. 2C shows a representative NKp46 and NKG2D staining for CD3-NK1.1+ NK
cells purified from splenocytes that were harvested 3 days after inoculation. Note that NKp46
staining for the experiments described in Fig. 2 was performed with commercial 29A1.4 mAb
that its binding did not overlap with NCR1.15 (Fig. 1D, E). NKp46 cell surface levels, but not
NKG2D levels, were considerably reduced following NCR1.15 injection as compared to PBS or
isotype control injections (Fig. 2C). Fig. 2D summarizes the NKp46 staining results for
Fig 2. Single dose treatment with NCR1.15 down-regulates the surface expression of NKp46 on NK
cells, but not the NKp46 transcript or spleen/blood NK levels. 3 days following i.p. injection of NCR1.15,
isotype control or PBS splenocytes (A, B) and PBMCs (B) were stained and analyzed for CD3-NK1.1+ NK
cells using flow cytometry. Data from one representative of five independent experiments are shown. The
membrane associated NKp46 (C, D) and NKG2D (C) on NK cells were stained and analyzed using flow
cytometry. (E) Representative confocal images of purified splenic NK cells stained for extra- and intracellular
expression of the NKp46. (F) qRT-PCR of NKp46 transcripts in splenocytes harvested from treated mice. (G)
GFP intensity (GeoMFI) expressed by NK cells from NCR1gfp/+ following the various treatments. Data from
one representative of three independent experiments are shown. ** p<0.01 by Student's unpaired t-test.
Bars, ±SD.
doi:10.1371/journal.pone.0118936.g002
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CD3-NK1.1+NK-gated splenocytes and PBMCs from four independent experiments. Cell-
membrane levels of NKp46 were significantly down-regulated following single dose injection
of NCR1.15 compared to mock injection (near 2-fold change). However, we also analyzed
NKp46 expression on CD3+NK1.1+ NKT cells, knowing that the NKp46 is expressed on subset
of these cells [31], and got similar reduction levels of NKp46 expression with no change in
NKT levels (data not shown). Further, to investigate whether this down-regulation at the cell
surface reflects suppression of NKp46 production or internalization of the protein, we studied
NKp46 localization employing confocal microscopy. Intracellular expression of NKp46 was
similar in the NK from either NCR1.15- or mock-treated mice, while membrane-associated
staining was reduced in the NK from NCR1.15-treated mice (Fig. 2E). Thus, it is probable that
NCR1.15 treatment neither suppressed NKp46 protein synthesis nor enhanced
NKp46 internalization.
Following the aforementioned results in the protein level, we hypothesized that single injec-
tion of anti-NKp46 would not suppress the activity of the NKp46 promoter or induce degrada-
tion of NKp46-encoding RNA. Indeed, qPCR analysis of NKp46-encoding mRNA showed that
NCR1.15 treatment did not affect the levels of transcribed NKp46 (Fig. 2F). To better address
the question for the NKp46 promoter activity, we employed Ncr1gfp/+ heterozygous mice ex-
pressing one allele encoding for mNKp46 and the other allele encoding for GFP under the con-
trol of Ncr1 promoter. NCR1.15 treatment did not alter GFP levels in NK cells compared to
mock-treated mice (Fig. 2G), indicating that a single dose injection of anti-NKp46 did not af-
fect Ncr1 promoter activity. To summarize, single dose injection of NCR1.15 significantly re-
duced membrane-associated levels of NK-expressed NKp46 but did not affect NKp46
transcription or translation.
We then studied whether down-regulation of membrane-associated NKp46 affects NK ac-
tivity using YAC-1 target cells, which are sensitive to NK activity. CD3-NK1.1+NK cells puri-
fied from splenocytes harvested 3 days after NCR1.15 inoculation significantly reduced vesicle
degranulation following incubation with YAC-1 target cells (Fig. 3A). To test whether this ob-
servation is correct in vivo,we mixed two fluorescently labeled target cells, NK-sensitive YAC-1
and NK insensitive RMA cells (1:1 ratio), and injected them intravenously 3 days after
NCR1.15/mock treatment of mice. YAC-1 and RMA cells were labeled with different fluores-
cent probes; thus we could differ between the two targets in the same lung. Lung clearance
assay of YAC-1 cells normalized on RMA cells was significantly lower in NCR1.15-treated
mice compared to PBS- or isotype control-treated mice (Fig. 3B). We extended our studies to
PD1.6 target cells that manifest sensitivity to NKp46-mediated NK function [32]. To better
compare effector cells, we mixed PD1.6 target cells with effector NK cells purified from both
isotype control- and NCR1.15-treated mice (1:1:1 ratio, E1:E2:T) and tested NK cell degranula-
tion. One effector NK population was derived fromWT C57BL/6 mice and the other was de-
rived from UBC-GFP C57BL/6 mice. Therefore, by detecting GFP, we could differ between the
two NK populations using a flow cytometry-based degranulation assay in the same well.
Fig. 3C shows a representative assay in which UBC-GFPmice were mock-treated, and WT
mice were NCR1.15-treated. With no target cells, the degranulation level was near zero and
similar between the two mixed NK effector populations. Following incubation with target
PD1.6 cells, the degranulation of mock-treated NK cells was significantly higher compared to
the NCR1.15-treated NK cells in the mixed population (Fig. 3C).
To further investigate whether this reduction in NK activity is general or NKp46-associated,
we employed as target cells Ba/F3 cells that express null levels of ligands to NKp46 and
NKG2D, transfected with the NKG2D ligand Rae1ε (Ba/F3-Rae1ε, Fig. 3D). Therefore, we
could test whether the suppressing effect of NCR1.15 treatment is restricted to NKp46-mediat-
ed NK function. With no target cells, the degranulation level was near zero and similar between
Targeting NK Reactivity by mAb to NKp46
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the two NK effector populations. Following incubation with Ba/F3-Rae1ε target cells, degranu-
lation was observed, but with no significant difference between NK cells derived from either
mock- or NCR1.15-injected mice (Fig. 3D). To summarize, one injection of NCR1.15 specifi-
cally induced NKp46-associated reduction of NK function when tested 3 days after treatment.
Treatment with NCR1.15 inhibited LDSTZ-induced diabetes
We have shown that a single treatment with NCR1.15 was able to reduce NKp46-associated
NK function on NKp46-sensitive target cell lines. Primary β-cells in the islets of Langerhans
were reported to serve as targets to NK cells and that NKp46 is primarily involved [33]. Indeed,
Fig 3. Single dose treatment with NCR1.15 inhibits NKp46-mediated activity on NK cells. (A) 3 days
following i.p. injection of NCR1.15, isotype control or PBS purified splenic NK cells were co-incubated for 2–4
hours with YAC-1 target cells in the presence of anti-CD107a antibody. CD107a surface levels on NK cells
were assessed by FACS. (B) Labeled YAC-1 and RMA cells were injected into the tail vein of 5 NCR1.15-, c-
IgG1 κ- or PBS-treated mice. Cells in the lungs were quantified 3–4 hours following the injection using FACS
analysis. Data from one of two independent experiments are shown. (C) 3 days following mice i.p. injection c-
IgG1 κ-treatedUBC-GFP and NCR1.15-treated C57BL/6WT purified splenic NK cells were co-incubated
with PD1.6 target cells in 1:1:1 ratio (E1:E2:T) with the presence of anti-CD107a antibody for 3–4 hours.
CD107a surface levels on NK cells were assessed by FACS. (D) Purified splenic NK cells harvested from
control- or NCR1.15-treated mice 3 days after the treatment were co-incubated with Ba/F3-Rae1ε target
cells in 1:1 E:T ratio for 3–4 hours. CD107a surface expression levels were analyzed using FACS. Data from
one representative of three independent experiments are shown. ** p<0.01 by Student's unpaired t-test.
Bars, ±SD.
doi:10.1371/journal.pone.0118936.g003
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co-incubation of pancreatic primary beta cells from naïve mice with NK cells derived from
NCR1.15 single injection treated mice, both from C57BL/6 origin, resulted in significantly re-
duced degranulation levels (Fig. 4A). We next investigated whether NCR1.15 short-term treat-
ment could affect the early development of diabetes. An accepted model of experimental
autoimmune diabetes in mice is the induction of diabetes by multiple injections of a low dose
of streptozotocin (LDSTZ) [34–36]. A single NCR1.15 treatment comprises a single 100 μg/
mouse injection. Here, we treated mice once with NCR1.15 (50 μg/mouse) followed by 5 conse-
cutive days of i.p. injections with STZ and completed with additional NCR1.15 treatment
(Fig. 4B, inset). The NCR1.15 treatment significantly impaired diabetes development. Hyper-
glycemia, defined as a non-fasting blood glucose concentration of300 mg/dl in two sequen-
tial measurements, was significantly less severe in NCR1.15-treated mice compared to a mock
treatment group (Fig. 4B). Accordingly, reduction in body weight of the NCR1.15-treated mice
was significantly lower than that of the control mice, indicating the healthier status of
NCR1.15-treated mice (Fig. 4C). Additionally, histological analysis of the pancreas showed re-
duced mononuclear infiltration and reduced insulitis score for the islets within NCR1.15-treat-
ed mice as compared to mock-treated group (Fig. 4D, E). To sum up, these results indicate that
Fig 4. Short term treatment with NCR1.15 down-regulates NKp46-mediated activity on pancreatic β-cells and inhibits LD-STZ induced diabetes. (A)
Purified splenic NK cells from treated cells were co-incubated for 2–4 hours with purified C57BL/6 β-cells in the presence of anti-CD107a antibody. CD107a
surface levels on NK cells were assessed by FACS. * p<0.05 by Student's unpaired t-test. (B) LD-STZ induced diabetes development in C57BL/6 mice
following 50μg injections at days-2 and 5. (n = 8). Animals were considered diabetic when blood glucose was300mg/dl. *** p<0.005 Kaplan-M log-rank
(Mental-Cox). (C) Body weight of mice in the indicated groups following the LD-STZ administration; body weight baselines at day 0 of the control and
NCR1.15 groups were 19.2±0.86, 19.8±1 grams, respectively. * p<0.05, ** p<0.01, *** p<0.005 by Student's unpaired t-test. Bars, ±SD. (D)
Representative H&E sections of the pancreas from sex&age-matched C57BL/6 mice treated with NCR1.15 or mock-treated (IgG1, κ) in LD-STZ induced
diabetes model (magnification X40). (E) Summary of insulitis score over the days calculated as described in [37]. Score is quantified from 0 (low) to 4 (most
severe).
doi:10.1371/journal.pone.0118936.g004
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NKp46 is important for the development of diabetes and the destruction of islets in the
LDSTZ model.
Repeated long-term treatments with NCR1.15 inhibited T1D
development in NODmice
We have previously shown that beta cells specifically express the ligand for the NK-activating
receptor NKp46/Ncr1 and that NK cells kill beta cells in an NKp46/Ncr1-dependent manner
[10,33]. Furthermore, we have shown that anti-mNKp46/Ncr1 antibodies generated through
active immunization inhibit T1D development [10]. To recapitulate these observations, we in-
vestigated the effect of repeated NCR1.15 treatments in C57BL/6 mice. WT mice were treated
with NCR1.15 every other day for two weeks and both PBMCs and splenocytes were tested 3
days following the last injection. Our results were very similar to those observed for one
NCR1.15 inoculation (Figs. 2, 3). The fraction of NK cells in PBMCs and the spleen did not
change between NCR1.15- and mock-treated mice (Fig. 5A). We also employed the protocol of
prolonged multiple injections of NCR1.15 to Ncr1gfp/+ mice and tested for the fraction of GFP-
positive cells indicating NK fraction [20] and for GFP intensity indicating Ncr1 gene promoter
activity. Neither the numbers of GFP+ nor the GFP intensity was different between NCR1.15-
and mock-treated mice (Fig. 5B). In contrast, membrane-associated NKp46 expression was sig-
nificantly reduced in PBMCs and in splenocytes harvested from mice that had undergone pro-
longed multiple NCR1.15 treatments compared to mock-treated mice (Fig. 5C, D). As with the
single NCR1.15 injection, this reduction was not due to reduced Ncr1 gene promoter activity as
deduced from qRT-PCR levels of the Ncr1 transcript (Fig. 5E) and from the Ncr1-encoded
GFP levels (Fig. 5B). Since treatment lasted for two weeks and mice were tested 3 days later, we
could investigate whether NCR1.15 treatment conferred changes in NK subsets representing
developmental NK stages. Antibodies to CD3, NK1.1, CD27, and CD11b were used to define
CD3-NK1.1+CD11blowCD27+, CD3-NK1.1+CD11b+CD27+ and CD3-NK1.1+CD11b+CD27low
NK developmental stages. No significant difference was observed between NCR1.15- and
mock- treatment for cell numbers among the NK developmental stages. In contrast, mem-
brane-associated NKp46 levels were significantly reduced in NCR1.15-treated mice in all stud-
ied NK developmental stages as shown in S1 Fig.
We then studied repeated long-term NCR1.15 treatments in NODmice. As for C57BL/6
mice, NCR1.15 treatment of NOD mice did not affect number of NK cells (Fig. 6A), but it did
significantly reduce membrane-associated NKp46 expression (Fig. 6B, C). To directly demon-
strate that blocking of NKp46 in NODmice will block diabetes development, we injected
NCR1.15 into NODmice every other day (100μg per injection) beginning in week eight. As
shown in Fig. 6D, repeated NCR1.15 treatment significantly inhibited T1D development in
NOD female mice compared to treatment with PBS or isotype Ab control.
Discussion
We have recently reported that NKp46, a primary activating receptor expressed by NK cells,
recognizes ligands expressed by islet β-cells, and that in the absence of NKp46 diabetes devel-
opment is inhibited [10,33]. In the current study, we investigated whether treatment of mice
with NKp46 specific monoclonal antibody could down-regulate NKp46-mediated NK function
and inhibit T1D development. We developed the NCR1.15 mAb, which specifically recognizes
mNKp46 (Fig. 1) and showed that treatment of mice with NCR1.15 reduces NKp46 mem-
brane-associated expression by NK cells (Fig. 2). This reduction was paralleled by reduced
NKp46-mediated NK function (Fig. 3). NCR1.15 treatment did not reduce the fraction of NK
cells in the blood or the spleen; neither did it affect the NKG2D-mediated function of NK cells
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(Figs. 2, 3). This NKp46-specific reduction in NK function was shown both in vitro and in vivo
(Fig. 3). Finally, we showed that multiple treatments with NCR1.15 inhibited development of
diabetes in the LDSTZ model and in NODmice (Figs. 4, 6). Acquired histopathological data
for the LDSTZ model indicate that development of insulitis is attenuated in NCR1.15-treated
mice as compared to mock-treated mice (Fig. 4).
Targeted immunotherapy involving treatment with antibodies to activate immune cellular
receptors and immune molecules holds great promise for the treatment and cure of autoim-
mune and inflammatory diseases [38,39]. In particular, Ab-mediated modulation of immune
effector receptors and receptor-expressing cells have been widely studied for the TCR [38,40].
Modulation of the TCR-CD3z by specific antibodies has been suggested to down-regulate T
cell function through (i) antigenic modulation (suppression) of the cell-surface TCR, (ii) deple-
tion of the T cells, and /or (iii) the anergy of T cells [40,41]. We have shown that treatment
with anti-NKp46 resulted in antigenic modulation of NK-expressed NKp46, but not in general
NK depletion. Anergy wise, our treatment induced down-regulation of NKp46-specific NK
function, but it did not induce general NK anergy, as tested by NKG2D function (Fig. 3D).
Down-regulation of NK function following exposure to anti-NKp46 mAb has also been re-
ported by Jewett et al. [42]. However, Narni-Mancinelli et al. reported a more complex pheno-
type [43]: short time treatment with anti-NKp46 resulted in reduced NKp46-mediated NK
function in accordance with our results and other reports [42] even though long time-treat-
ment caused enhanced NKp46-mediated NK function [43]. This observation for long-time
treatment was not reported by others nor us, and could stem from the diphtheria toxin-mediat-
ed whole NK depletion performed before the long time treatment [43]. Yet entire NK cell
Fig 5. Prolongedmultiple treatments with NCR1.15 down-regulates the surface expression of NKp46.Mice were injected i.p. 8 doses of PBS, 100 μg
of NCR1.15 or cIgG1,κ every other day; 3 days after the last inoculation mice were sacrificed for further analysis. (A) C57BL/6WT PBMCs and splenocytes
were harvested and stained to detect the levels of CD3-NK1.1+ NK cells. Data from one representative of three independent experiments are shown. (B)
PBMCs drained from NCR1gfp/+mice were analyzed for GFP expression following the prolonged repeated treatments. (C, D) Membrane associated NKp46
and NKG2D levels were analyzed on gated CD3ε-NK1.1+ NK cells. (E) NCR1 transcript levels from treated mice splenocytes were assessed by qRT-PCR.
Data from one representative of two independent experiments are shown. * p<0.05, ** p<0.01 by Student's unpaired t-test. Bars, ±SD.
doi:10.1371/journal.pone.0118936.g005
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depletion before treatment with anti-NKp46 does not represent a plausible treatment regimen
in humans.
Several groups reported that treatment of T1D with mAb specific to CD3 resulted in a sig-
nificant therapeutic effect through the antigenic modulation of the TCR-CD3z complex (re-
viewed in [40]). However, others have shown that this therapeutic effect was due to induction
of T cell anergy or apoptosis of activated T cells [44]. T1D disease is considered to be mainly
driven by the activation of T-lymphocytes against pancreatic β-cells [45]. However, findings
support the view that T1D can be regarded as an innate inflammatory disease affecting the en-
tire pancreas, but with its main clinical manifestations emanating from the loss of the insulin-
producing cells [46]. In this respect, we, among others, have shown that NK cells contribute to
the early stage of T1D development [10,20]. The question then arose whether treatment with
mAb targeting NK activating receptors can have a therapeutic benefit for T1D. The NKG2D re-
ceptor is a primary activating receptor for NK cells and a co-stimulatory receptor for T cells.
Blockage of NKG2D prevented T1D in NODmice. The mechanism reported involved blockage
of NKG2D receptors to their ligands, as well as internalization of the receptor. However, no de-
pletion of NK cells or CD8+ T cells was observed [47]. NKp46 is a major NK activating recep-
tor, and it is mostly restricted to NK cells compared to the broader expression spectrum of
NKG2D. We demonstrated that β-cells both human and mouse islets express ligand(s) for
NKp46 [10,33]. We also showed that in the absence of NKp46 diabetes development is inhib-
ited. We then proved that NKp46 is involved in the direct killing of human islets β-cells that
are intended to be used for transplantation [10,33]. The NKp46 ligand is detected on healthy
mouse β-cells, but we demonstrated that NK cells were absent from the vicinity of the islets in
healthy mice and were detected in situ in proximity with β-cells in NODmice [10,33]. In this
Fig 6. Treatment with NCR1.15 reduces NKp46-mediated NK activity on β-cells and inhibits T1D
development. (A) 8 weeks after the first treatment NOD PBMCs drained frommice within the indicated
groups were stained and analyzed for NK levels. NK cell levels were normalized to mock (PBS) treatment. (B)
Representative histogram of membrane associated NKp46 levels on gated CD3ε-CD49b+ NK cells from the
indicated groups. (C) Normalized GeoMFI of membrane associated NKp46 on gated NK cells, ** p<0.01 by
Student's unpaired t-test. GeoMFI values were normalized to mock (PBS) treatment. (D) T1D development in
NOD female mice in the indicated groups. (n = 14–15). Animals were considered diabetic when blood
glucose was250mg/dl. * p<0.05 Kaplan-M log-rank (Mental-Cox). Bars, ±SD.
doi:10.1371/journal.pone.0118936.g006
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study, we have investigated a treatment based on the inoculation of mAb specific for NKp46.
Following treatment, NK cells were not depleted nor did they undergo general anergy. Even so,
we observed a very clear antigenic modulation of membrane-associated NKp46 and NKp46
specific NK function that was followed by a significant impairment of T1D development. It
will be interesting to further explore whether the combination of both anti-NKp46 and anti-
NKG2D mAbs will lead to an even more pronounced delayed onset of this disease.
To summarize, in this study, we have shown that anti-NKp46 treatment was sufficient to
significantly delay diabetes early development in LDSTZ and NODmodels. Both, short-term
and repeated long-term treatments with anti-NKp46 mAb resulted in an NKp46-specific im-
pairment of NK function without NK depletion. This treatment represents a pinpoint-targeted
therapeutic approach intended to specifically remove/reduce the NKp46 component in NK
function neither harming non-NKp46 mediated NK activity nor affecting T cells.
Supporting Information
S1 Fig. Membrane-associated NKp46 levels in different NK developmental stages (Y-axis in
histogram representation). The membrane-associated NKp46 expression was significantly re-
duced in NCR1.15 treated mice comparing to control treatments in all studied NK
developmental stages.
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